18F-PSMA-1007 is a novel prostate-specific membrane antigen (PSMA)–based radiopharmaceutical for imaging prostate cancer (PCa). The aim of this study was to compare the diagnostic accuracy of 18F-PSMA-1007 with 68Ga-PSMA-11 PET/CT in the same patients presenting with newly diagnosed intermediate- or high-risk PCa. Methods: Sixteen patients with intermediate- or high-risk PCa underwent 18F-PSMA-1007 and 68Ga-PSMA-11 PET/CT within 15 d. PET findings were compared between the 2 radiotracers and with...
Mark above section as read
Publication date: Available online 1 April 2020Source: Clinical ImagingAuthor(s): Rebecca T. Sivarajah, Alison Chetlen, Karen Brown
Publication date: Available online 31 March 2020Source: Clinical ImagingAuthor(s): Katerina Dodelzon, Andrew D. Schweitzer
Publication date: Available online 31 March 2020Source: Clinical ImagingAuthor(s): E. di Pasquo, A.J.O. Kiener, A. DallAsta, A. Commare, L. Angeli, T. Frusca, T. Ghi
Publication date: Available online 31 March 2020Source: Clinical ImagingAuthor(s): Frank Chen, Neema Patel, Jordan Legout, Melanie Caserta
Mark above section as read
Publication date: Available online 31 March 2020Source: European Journal of Vascular and Endovascular SurgeryAuthor(s): Athanasios Katsargyris, Vasuki Uthayakumar, Pablo M. de Marino, Balazs Botos, Eric L. Verhoeven
Wed Apr 01, 2020 16:08
Publication date: Available online 31 March 2020Source: European Journal of Vascular and Endovascular SurgeryAuthor(s): David Barillà, Francesco La Corte, Filippo Benedetto
Wed Apr 01, 2020 16:08
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου